Medarex, Inc. Shares Fall Monday On Concerns Over Late-Stage Melanoma Drug Candidate Ipilimumab

NEW YORK (AP) -- Shares of biotechnology company Medarex Inc. fell Monday after analysts expressed concerns over the company's late-stage melanoma drug candidate ipilimumab. Shares fell 63 cents, or 7.2 percent, to $8.08.